Currently, several HIF-2α inhibitors are also being tested in clinical trials (Choi et al., 2021), and HIF-2α inhibitor belzutifan was approved for use in VHL-associated cancers (Sheridan, 2021). This evidence concerns the gene VHL and cancer.